Mostrar el registro sencillo del ítem

dc.contributor.authorGonzález Correa, Cristina 
dc.contributor.authorMoleón Moya, Javier 
dc.contributor.authorMiñano, Sofía
dc.contributor.authorRobles Vera, Iñaki 
dc.contributor.authorToral Jiménez, Marta
dc.contributor.authorBarranco, Antonio Manuel
dc.contributor.authorMartín Morales, Natividad 
dc.contributor.authorO´Valle, Francisco
dc.contributor.authorGuerra Hernández, Eduardo Jesús 
dc.contributor.authorSánchez, Manuel
dc.contributor.authorGómez Guzmán, Manuel 
dc.contributor.authorJiménez Moleón, Rosario 
dc.contributor.authorRomero Pérez, Miguel 
dc.contributor.authorDuarte Pérez, Juan Manuel 
dc.date.accessioned2024-05-22T06:47:27Z
dc.date.available2024-05-22T06:47:27Z
dc.date.issued2024-05-21
dc.identifier.citationGonzález-Correa, C. et al. Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first-line antihypertensive drugs. British Journal of Pharmacology, 1–25. (2024) https://doi.org/10.1111/bph.16410es_ES
dc.identifier.urihttps://hdl.handle.net/10481/91942
dc.descriptionhttps://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.16410es_ES
dc.descriptionThis work was supported by Grants from Agencia Estatal de Investigación (AEI), Ministerio de Ciencia e Innovación (MCIN) (PID2020-116347RB-I00 funded by MCIN/AEI/10.13039/501100011033) and Junta de Andalucía (CTS 164, P20_00193 and A-CTS-318-UGR20) with funds from the European Union and by the Ministerio de Economia y Competitividad, Instituto de Salud Carlos III (CIBER-CV), Spain. M.T. and I.R.-V. are postdoctoral fellow of Spanish Ministerio de Ciencia e Innovación (Juan de la Cierva Incorporación Program, IJC2020-044581-I, and Juan de la Cierva Formación Program, respectively). J. M. is a predoctoral fellow of MCIN, and C. G.-C. and S. M. are predoctoral fellow of Junta de Andalucía. The cost of this publication was paid in part with funds from the European Union (Fondo Europeo de Desarrollo Regional, FEDER, ‘FEDER una manera de hacer Europa’).es_ES
dc.description.abstractBackground and Purpose: This study analyses whether first-line antihypertensive drugs ameliorate the dysbiosis state in hypertension, and to test if this modification contributes to their blood pressure (BP) lowering properties in a genetic model of neurogenic hypertension. Experimental Approach: Twenty-week-old male Wistar Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) were untreated or treated with captopril, amlodipine or hydrochlorothiazide. A faecal microbiota transplantation (FMT) experiment was also performed by gavage of faecal content from donor SHR-treated groups to SHR recipients for 3 weeks. Key results: Faeces from SHR showed gut dysbiosis, characterized by lower acetate- and higher lactate-producing bacteria and lower strict anaerobic bacteria. All three drugs increased the anaerobic bacteria proportion, captopril and amlodipine restored the proportion of acetate-producing bacterial populations to WKY levels, whereas hydrochlorothiazide decreased butyrate-producing bacteria. Captopril and amlodipine decreased gut pathology and permeability and attenuated sympathetic drive in the gut. Both drugs decreased neuroinflammation and oxidative stress in the hypothalamic paraventricular nuclei. Hydrochlorothiazide was unable to reduce neuroinflammation, gut sympathetic tone and gut integrity. FMT from SHR-amlodipine to SHR decreased BP, ameliorated aortic endothelium-dependent relaxation to acetylcholine, lowered NADPH oxidase activity, aortic Th17 infiltration and reduced neuroinflammation, whereas FMT from SHR-hydrochlorothiazide did not have these effects. Conclusions and Implications: First-line antihypertensive drugs induced different modifications of gut integrity and gut dysbiosis in SHR, which result in no contribution of microbiota in the BP lowering effects of hydrochlorothiazide, whereas the vasculo-protective effect induced by amlodipine involves gut microbiota reshaping and gut-immune system communication.es_ES
dc.description.sponsorshipUniversidad de Granadaes_ES
dc.description.sponsorshipMCIN/AEI/10.13039/501100011033 PID2020-116347RB-I00es_ES
dc.description.sponsorshipJunta de Andalucía (CTS 164, P20_00193 and A-CTS-318-UGR20)es_ES
dc.description.sponsorshipEuropean Uniones_ES
dc.description.sponsorshipMinisterio de Economía y Competitividad, Instituto de Salud Carlos III (CIBER-CV)es_ES
dc.description.sponsorshipSpanish Ministerio de Ciencia e Innovación IJC2020-044581-Ies_ES
dc.description.sponsorshipJunta de Andalucíaes_ES
dc.description.sponsorshipFondo Europeo de Desarrollo Regional, FEDERes_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAmlodipinees_ES
dc.subjectCaptopriles_ES
dc.subjectEndothelial dysfunctiones_ES
dc.subjectGut dysbiosises_ES
dc.subjectHydrochlorothiazidees_ES
dc.subjectHypertensiones_ES
dc.subjectImmune systemes_ES
dc.titleDiffering contributions of the gut microbiota to the blood pressure lowering effects induced by first-line antihypertensive drugses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1111/bph.16410
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional